Ginna G. Laport

Publications

• Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM. J Clin Oncol. 2013; 31 (12): 1530-8
• Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, Freytes CO, Bolwell BJ, Hsu JW, Slavin S, Isola L, Rizzieri DA, Gale RP, Laport GG, Montoto S, Lazarus HM, Hari PN. Biol Blood Marrow Transplant. 2012; 18 (7): 1036-1043.e1
• Changing role of stem cell transplantation in follicular lymphoma. Laport GG, Hematology Am Soc Hematol Educ Program. 2012: 2012 417-25
• Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. Sehn LH, Fenske TS, Laport GG. Biol Blood Marrow Transplant. 2012; 18 (1 Suppl): S82-91
• Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Müller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino AE, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA. Biol Blood Marrow Transplant. 2012; 18 (1): 125-33
• Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. Jagasia MH, Abonour R, Long GD, Bolwell BJ, Laport GG, Shore TB, Durrant S, Szer J, Chen MG, Lizambri R, Waller EK. Bone Marrow Transplant. 2012; 47 (10): 1350-5
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB. Blood. 2012; 119 (25): 6145-54
• Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Bone Marrow Transplant. 2012; 47 (4): 581-8
• Tandem transplantation for follicular lymphoma: the best of both worlds? Laport GG, Biol Blood Marrow Transplant. 2012; 18 (6): 820-1
• Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Biol Blood Marrow Transplant. 2011; 17 (11): 1679-87
• Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG. Lancet Oncol. 2011; 12 (13): 1195-203
• Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG. Biol Blood Marrow Transplant. 2011; 17 (7): 1051-7
• Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R. JAMA. 2011; 306 (17): 1874-83
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L. Bone Marrow Transplant. 2011; 46 (2): 192-9
• Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Benjamin JE, Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R, Laport GG. Bone Marrow Transplant. 2010; 45 (2): 303-9
• Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy. Laport GG, Curr Opin Oncol. 2010; 22 (5): 409-13
• Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Biol Blood Marrow Transplant. 2010; 16 (8): 1145-54
• The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Oliansky DM, Gordon LI, King J, Laport G, Leonard JP, McLaughlin P, Soiffer RJ, van Besien KW, Werner M, Jones RB, McCarthy PL, Hahn T. Biol Blood Marrow Transplant. 2010; 16 (4): 443-68
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Blood. 2009; 114 (5): 1099-109
• Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review. Laport GG, Leuk Lymphoma. 2008; 49 (10): 1854-9
• Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma. Dreger P, Laport GG. Biol Blood Marrow Transplant. 2008; 14 (1 Suppl 1): 100-7
• Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, Wong RM, Negrin RS, Blume KG, Forman SJ. Blood. 2008; 112 (3): 903-9
• Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG. Biol Blood Marrow Transplant. 2008; 14 (7): 741-7
• Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF. Biol Blood Marrow Transplant. 2008; 14 (2): 246-55
• Mantle cell lymphoma in first complete remission. Laport GG, Biol Blood Marrow Transplant. 2007; 13 (9): 1118-9
• High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE. Biol Blood Marrow Transplant. 2006; 12 (7): 703-11
• The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma. Laport GG, Biol Blood Marrow Transplant. 2006; 12 (1 Suppl 1): 59-65
• CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R. Exp Hematol. 2005; 33 (3): 279-85
• Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R. Blood. 2005; 105 (6): 2300-6
• Protective conditioning for acute graft-versus-host disease. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S. N Engl J Med. 2005; 353 (13): 1321-31
• Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Tong J, Laport G, Lowsky R. Bone Marrow Transplant. 2005; 36 (8): 739-40
• Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. Kebriaei P, Winter JN, Laport GG, Le Beau MM, Dewald G, Larson RA. Leuk Res. 2004; 28 (5): 537-40
• Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH. Blood. 2003; 102 (6): 2004-13
• Nonmyeloablative allogeneic stem cell transplantation for acute leukemia. Laport GG, Curr Hematol Rep. 2003; 2 (1): 49-56
• A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Laport GG, Fleming GF, Waggoner S, Zimmerman TM, Grinblatt DL, Williams SF. Bone Marrow Transplant. 2001; 27 (7): 677-81
• Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH. Biol Blood Marrow Transplant. 2001; 7 (4): 230-8
• A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies. Sobecks RM, Daugherty CK, Hallahan DE, Laport GF, Wagner ND, Larson RA. Bone Marrow Transplant. 2000; 25 (8): 807-13
• Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. Mathias C, Mick R, Grupp S, Duffy K, Harris F, Laport G, Stadtmauer E, Luger S, Schuster S, Wasik MA, Porter DL. J Hematother Stem Cell Res. 2000; 9 (3): 393-400
• Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer. Laport GG, Valone FH, Zimmerman TM, Grinblatt DL, Van Vlasselaer P, Still BJ, Williams SF. Cytotherapy. 2000; 2 (3): 179-85
• High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Laport GF, Grad G, Grinblatt DL, Bitran JD, Williams SF. Bone Marrow Transplant. 1998; 21 (2): 127-32
• The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Laport GF, Williams SF. Semin Oncol. 1998; 25 (4): 503-17
• Treatment of adult acute lymphoblastic leukemia. Laport GF, Larson RA. Semin Oncol. 1997; 24 (1): 70-82